Log In Sign up
The largest database of trusted experimental protocols
> Anatomy > Body System > System, Endocrine

System, Endocrine

The Endocrine System is a complex network of glands and hormones that regulates numerous physiological processes in the body.
It plays a crucial role in maintaining homeostasis, mediating growth and development, and influencing metabolism, reproduction, and mood.
This system includes the pituitary, thyroid, parathyroid, adrenal, and pancreatic glands, as well as other specialized endocrine tissues.
Hormones secreted by these glands travel through the bloodstream to target tissues, where they elicit specific effects.
Disruptio ns or imbalances in the Endocrine System can lead to a variety of disorders, such as diabetes, thyroid diseases, and hormonal cancers.
Understanding the Endocrine System is essential for researchers investigating endocrine-related health conditions and developing effective treatments.

Most cited protocols related to «System, Endocrine»

1
Consensus Conference on Digestive Endocrine Tumors
Sixty-two experts in the field of digestive endocrine tumors from 20 different countries attended the Consensus Conference. The attendees represented all medical branches involved in managing patients with gastroenteropancreatic NETs. They formed four working groups according to their specific clinical expertise: (1) pathology and genetics (11 participants, all listed as authors and G. Klöppel), (2) surgery (10 participants, including the coauthors H. Alhman and M. Falconi), (3) imaging and radiology (10 participants), (4) medicine and clinical pathology (31 participants, including the coauthors M. Caplin, W.W. de Herder, B. Erikssson, and B. Wiedenmann).
The Conference was divided sequentially into eight sessions devoted to specific topics on an anatomical basis (gastric NET sessions 1–2, duodenal NET, pancreatic NET sessions 1–4, and poorly differentiated endocrine carcinomas). A working booklet with the ENETS guidelines and specific queries had been prepared in advance by the Organizing Committee. The work was organized such that, after a short case presentation in a plenary session, each working group gathered separately to discuss group-specific questions. Once agreement was reached within each group, consensus statements were discussed and approved or rejected by all participants gathered in the plenary session. This procedure was followed for all eight sessions. The TNM staging proposal was made by the Pathology and Genetics working group and amended and approved by the plenary session of the consensus conference. The grading system was discussed and defined by the Pathology and Genetics working group only.
Rindi G., Klöppel G., Alhman H., Caplin M., Couvelard A., de Herder W.W., Erikssson B., Falchetti A., Falconi M., Komminoth P., Körner M., Lopes J.M., McNicol A.M., Nilsson O., Perren A., Scarpa A., Scoazec J.Y, & Wiedenmann B. (2006). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 449(4), 395-401.
Publication 2006
Carcinoma of Endocrine Gland Conferences Digestive System Duodenum Endocrine Gland Neoplasms Gastro-enteropancreatic neuroendocrine tumor Gastrointestinal Neoplasms Operative Surgical Procedures Pancreas Patients Pharmaceutical Preparations Stomach System, Endocrine X-Rays, Diagnostic
2
EQ-5D Measurement Properties Evaluation
This study aimed at assessing measurement properties for 3L and 5L in eight broad patient groups. A student cohort was added in order to investigate how both instruments perform in a healthy population sample. Respondents completed both the 3L and 5L in six countries: Denmark, England, Italy, the Netherlands, Poland, and Scotland. Data collection in Denmark was conducted through the endocrinology, rheumatology, and orthopedic departments of a regional university hospital. Data collection in England was organized through a specialist patient recruitment agency and aimed at patients with prespecified conditions. In Italy the cohort of liver disease patients completed the questionnaires locally at two hospitals (Bergamo and Naples). Data collection in the Netherlands was conducted at a specialist center for personality disorders and at a local hospital for the kidney dialysis patients. In Poland, the student cohort was recruited at the Medical University of Warsaw in Poland, and the stroke cohort was recruited through the Neurological Clinic in Warsaw. Data collection in Scotland took place through a specialist patient recruitment agency, with patients completing the questionnaires at primary care centers. Paper and pencil versions of the questionnaires were used in all countries except in England where data collection took place online. Data collection took place between August 2009 and September 2010. The 5L was administered first, followed by the EQ-5D visual analogue scale (EQ-VAS) and a number of demographic questions, then the 3L, and finally a set of five dimension-specific rating scales. All respondents scored 5L first, as a previous study showed a tendency to avoid the in-between levels 2 and 4 of 5L when responding to the 3L first [20 (link)]. Data collection was undertaken with informed consent and according to the ethical guidelines for health research in each country.
Janssen M.F., Pickard A.S., Golicki D., Gudex C., Niewada M., Scalone L., Swinburn P, & Busschbach J. (2012). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research, 22(7), 1717-1727.
Publication 2012
Cerebrovascular Accident Hemodialysis Liver Diseases Patients Personality Disorders Population Health Primary Health Care Student System, Endocrine Visual Analog Pain Scale
3
Predicting Sensitivity to Breast Cancer Therapy
We combined the individual predictions into a testing algorithm for predicted sensitivity to adjuvant treatment of HER2-negative breast cancer with taxane-anthracycline chemotherapy: 1) sensitivity to endocrine therapy assessed based on an independently validated 165-gene index of endocrine sensitivity (high or intermediate SET index)21 (link); 2) resistance to chemotherapy predicted either by early distant relapse events or by extensive residual disease after neoadjuvant chemotherapy; and 3) sensitivity (pathologic response) to chemotherapy (Figure 1). Additional methodological details are provided in the Supplemental Appendix.
Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., Vidaurre T., Holmes F., Souchon E., Martin M., Cotrina J., Gomez H., Hubbard R., Chacón J.I., Ferrer-Lozano J., Dyer R., Buxton M., Gong Y., Wu Y., Ibrahim N., Andreopoulou E., Ueno N.T., Hunt K., Yang W., Nazario A., DeMichele A., O’Shaughnessy J., Hortobagyi G.N, & Symmans W.F. (2011). GENOMIC PREDICTOR OF RESPONSE AND SURVIVAL FOLLOWING TAXANE-ANTHRACYCLINE CHEMOTHERAPY FOR INVASIVE BREAST CANCER. JAMA, 305(18), 1873-1881.
Publication 2011
Anthracyclines erbb2 Gene Genes Hypersensitivity Malignant Neoplasm of Breast Neoadjuvant Chemotherapy Pharmaceutical Adjuvants Pharmacotherapy Relapse Residual Tumor System, Endocrine taxane Therapeutics
4
Consensus on Reproductive Aging Staging
STRAW+10 involved a 2-day, in-person meeting hosted at the 2011 Annual Meeting of NAMS. On the first day, international experts gave oral presentations reviewing recent data bearing on the goals, as part of a public symposium, followed by comments and discussion from the audience. The first two sessions focused on data from prospective cohort studies of midlife women, clinical findings related to trajectories of change in menstrual, endocrine and ovarian markers of reproductive aging, and data relevant to how these trajectories vary by ethnicity, body size, and smoking status. A particular focus was on patterns of change in AMH, inhibin B, FSH, estradiol and AFC and their inter-relationships. A third session focused on emerging evidence related to staging reproductive aging in the context of cancer treatment, chronic illness including cancer and HIV-AIDS, and endocrine disorders including polycystic ovarian syndrome (PCOS) and primary ovarian insufficiency (POI, otherwise known as premature ovarian failure). At the end of day one, a panel reviewed and participants discussed modifications that had been proposed by symposium speakers. STRAW+10 explicitly considered feasibility of applying criteria in low resource countries.
Subsequently, 41 invited scientists convened to develop consensus and propose modifications to the STRAW model. These participants had clinical and/or research experience in female reproductive aging and included scientists from several key research groups in the United States, Canada, Australia, the Netherlands and South Africa, representatives from the NIH funded cohort studies of midlife women that have biological samples60 (link) including SWAN, the Michigan Bone Health and Metabolism Study (MBHMS), SMWHS, Biodemographic Models of Reproductive Aging (BIMORA), and the Penn Ovarian Aging Study (POAS) as well as the Australian MWMHP, as well as junior investigators who submitted qualifying posters.
Three breakout groups were formed based on scientific expertise and interest. Group 1 reviewed criteria for STRAW Stages −4 to −2. Group 2 reviewed criteria for STRAW Stages −1 to +2. Each of these two groups was subdivided into two subgroups and assigned a rapporteur. Each subgroup proposed modifications to the STRAW paradigm separately, considering criteria for the relevant stages in healthy women and the weight of evidence concerning the appropriateness of applying these criteria to smokers and women regardless of body size. Each subgroup of Group 1 and of Group 2 then reviewed the recommendations of their paired subgroup and discussed points of disagreement until consensus was reached. Group 3 discussed staging in the context of endocrine disorders and chronic illness and proposed modifications. This group then integrated with one of the Group 1 or Group 2 subgroups.
On the second day, the 41 scientists convened to review and discuss proposed modifications. First, Group 1 and Group 2 reviewed the other group’s recommendations proposed on the previous day. In this way, all groups reviewed all stages under consideration (Stages −4 to +2) Then, the group at-large met to discuss each proposal and final recommendations were adopted by consensus. Preliminary recommendations of the STRAW+10 Workshop were presented at the NAMS annual meeting on September 22 with comments and requests for clarification considered by the STRAW+10 program committee.
Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W., Sherman S., Sluss P.M, & de Villiers T.J. (2012). EXECUTIVE SUMMARY of STRAW+10: Addressing the Unfinished Agenda of Staging Reproductive Aging. Climacteric : the journal of the International Menopause Society, 15(2), 105-114.
Publication 2012
Acquired Immunodeficiency Syndrome Biopharmaceuticals Body Size Bones Conferences Disease, Chronic Endocrine System Diseases Estradiol Ethnicity Females inhibin B Malignant Neoplasms Menstruation Metabolism Native American myopathy Ovarian Failure, Premature Ovary Polycystic Ovary Syndrome Reproduction Signs and Symptoms System, Endocrine Woman
5
Multicenter Study of Adrenal Surgery Outcomes

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Adrenalectomy Biopharmaceuticals Conn Syndrome Homo sapiens Operative Surgical Procedures Patients Regional Ethics Committees System, Endocrine Veins

Most recents protocols related to «System, Endocrine»

1
Hormonal Assessment for Fertility and Menopause
Not available on PMC !

Example 20

Fertility—Progesterone is one of the most important hormones for pregnancy with myriad functions from ensuring implantation of the egg into a healthy uterine wall, to ensuring embryo survival and prevention of immune rejection of the developing baby. Many other hormones act in concert with progesterone, like Follicular Stimulating Hormone (FSH) and Luteinizing Hormone (LH) and can be used to assess optimal fertility windows on a monthly basis. And in fact an over dominant production of estrogen can lead to progesterone deficiency and thus difficulty getting or staying pregnant. It is important that women not only monitor FSH and LH to determine optimal fertility for getting pregnant, but ensure that sufficient levels or progesterone are being produced to ensure pregnancy and viability of the fetus. A study from the British Medical Journal, 2012, demonstrated that a single progesterone level test can help discriminate between viable and nonviable pregnancies. Among women who had an ultrasound, 73 percent had nonviable pregnancies. But among women with progesterone levels below 3 to 6 nanograms per milliliter, the probability of a nonviable pregnancy rose to more than 99 percent (Gallos L et al. British Medical J, 2012).

Perimenopause—Monitoring hormone levels during the menopausal transition may help women better understand important changes in their body and allow them to make more informed decisions about health, diet, and lifestyle. According to Hale G E (Best Pract Res Clin Obstet Gynaecol, 2009), data from endocrine studies on women throughout the menopausal transition show changes in levels of steroid hormones and gonadotropins (Progesterone, Estrodiol, LH, FSH and AMH) and follicle-stimulating hormone undergoes the first detectable change while menstrual cycles remain regular. Erratic and less predictable changes in steroid hormones follow, especially with the onset of irregular cycles. Later serum hormone studies on the inhibins and anti-Mullerian hormone established that diminishing ovarian follicle number contributes to the endocrine changes with advancing reproductive age.

Many fertility issues revolve around genetic, anatomical or other disorders that may either prevent a woman from becoming pregnant and/or staying pregnant. Some of these disorders include hormonal imbalances, diabetes, a short or insufficient cervix, and acute or chronic infections. A cascade of genes has been implicated in the occurrence of getting and staying pregnant. These genes have been studied using genotyping, gene expression, and proteomic analysis to assess a woman's ability to stay pregnant.

In some embodiments the disclosed device focuses on detecting levels of Progesterone, LH, FSH, Estrodiol, AMH, genotyping, gene expression through RNA and methylome sequencing, qPCR and proteomic analysis for fertility and menopause management from menstrual blood or cervicovaginal fluid.

US11864740B2. Sample collection and preservation devices, systems and methods (2024-01-09). NextGen Jane, Inc. [US]. Inventors: Ridhi Tariyal [US], Stephen K. Gire [US].
Patent 2024
BLOOD Cervix Uteri Chronic Infection Diabetes Mellitus Diet Embryo Endocrine System Diseases Epigenome Estrogens Fertility Fetal Viability Follicle-stimulating hormone Gene Expression Genes Genes, vif Gonadotropins Hormones Human Body Human Follicle Stimulating Hormone Infant Inhibin Luteinizing hormone Medical Devices Menopause Menstrual Cycle Menstruation Mullerian-Inhibiting Hormone Ovarian Follicle Ovum Implantation Perimenopause Pregnancy Progesterone Reproduction Steroids System, Endocrine Transcription, Genetic Ultrasonography Uterus Woman
2
Hypothyroidism and Autoimmune Markers in Saudi Arabia
The Jazan Research Ethics Committee of the General Directorate of Health Affairs (Jazan), Ministry of Health, Saudi Arabia, approved the current study, which complies with the Declaration of Helsinki. All participants provided written informed consent. A total of 158 age-matched (30–60 years) male and female subjects were recruited for the current case–control study from King Fahad Central Hospital, the outpatient clinic (control), and the Endocrine and Diabetes Center (hypothyroid patients) in the Jazan area of southwest Saudi Arabia. These subjects were chosen at random from a population of Saudis primarily from the Jazan region. Samples were collected during the period from November 2018 to March 2019. At the time of diagnosis, AHT patients had high levels of thyroid-stimulating hormone and low levels of free thyroxine, as well as anti-thyroid peroxidase and/or anti-thyroglobulin autoantibodies. The healthy control group included subjects who had no history of thyroid or other autoimmune diseases, severe illness, or a chronic inflammatory condition.
Habibullah M.M., Hakamy A., Mansor A.S., Atti I.M., Alwadani A.A, & Kaabi Y.A. (2023). The Association of UCP2-866 G/A Genotype with Autoimmune Hypothyroidism in the Southwestern Saudi Arabia Population. International Journal of General Medicine, 16, 875-879.
Publication 2023
anti-thyroglobulin antibody Autoimmune Diseases Diabetes Mellitus Diagnosis Disease, Chronic Ethics Committees, Research Healthy Volunteers Hypothyroidism Inflammation Iodide Peroxidase Males Patients System, Endocrine Thyroid Gland Thyrotropin Thyroxine Woman
3
Cancer Survivors' Return to Work Experiences
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Human Research Ethics Committee of the Affiliated Hospital of Nantong University (No.201,915). All participants provided written informed consent before participating in the study. Inclusion criteria for enrollment of patients in the study were: [1 (link)] age 18 to 60 years old; [2 (link)] diagnosis of cancer; [3 (link)] completed the treatment plan formulated by the physician based on the condition, and the results of the tumor imaging and/or markers showed that only regular monitoring is required; [4 (link)] working before treatment and had returned to work by the start of the study; [5 (link)] understand their own conditions; The exclusion criteria were: [1 (link)] other severe systemic complications and [2 (link)] diagnosis of stage IV cancer. The sample size is based on data saturation. From June 2019 to January 2020, with the support of the Nantong Cancer Friends Association, the researchers visited cancer patients’ group exercise sites (where patients usually work out in pairs) and the Cancer Friends Association’s science halls (where patients usually share their recovery experiences with each other) in the field. Then, using purposive sampling, the researcher recruited the first three patients who were considered to be informative. After completing interviews with these three patients, the researcher used snowball sampling to obtain contact information for additional patients and to schedule appointments with them for interviews. Data saturation was achieved when interviews with 25 patients were finished. To build the theory and refine it, the researchers recruited 5 patients with some special characteristics and experiences by theoretical sampling. Finally, 30 patients (numbered N1 to N30 according to the interview order) participated in the study. (Table 1).

Basic information of interviewees

Serial numberAgeGenderCancer siteCancer stagingTreatment modeWork before illnessCurrent JobTime to end treatment (months)
N156WomanBreastIIIR、C、TTeacherTeacher119
N242ManLungIIIR、C、TCivil servantsCivil servants26
N349WomanBreastIIOp、C、RRear-serviceLibrarian40
N446WomanThyroidIIIOpWorkerRear-service190
N550WomanOvaryIIIOp、CCivil servantsCivil servants41
N653ManNasopharynxIIOp、C、RSelf-employedEngineering contractor25
N758ManLungIIIOp、CCookRetailer61
N853ManRectumIIIOp、C、RRetailerRetailer74
N959ManRectumIIOp、CCivil servantsCivil servants59
N1047WomanBreastIIIOp、C、RCivil servantsCivil servants63
N1157ManColonIIOp、CWorkerCemetery keeper97
N1234WomanBreastIIOp、CCompany staffCompany staff43
N1334WomanBreastIIIOp、CCivil servantsCivil servants49
N1443WomanBreastIOp、CCompany staffInsurance salesman72
N1555ManLiverIIIC、OpStreet clerkStreet clerk35
N1659ManStomachIIOp、CTeacherVolunteer61
N1753WomanBreastIIIOp、C、REnterprise leadersEnterprise leaders48
N1849WomanLungIIIOp、C、RSelf-employedSelf-employed73
N1950WomanCervixIIOpICU nurseOrthopedic nurse84
N2041WomanSkinIIOpNurseNurse181
N2127WomanGulletIIOpDoctorDoctor61
N2240WomanBreastIIR、E、OpHead nurseNurse60
N2335ManRectumIIIOp、C、RDoctorDoctor72
N2436WomanStomachIIIOpDoctorResearcher36
N2552WomanColonIIIOp、CDoctorResearcher34
N2646ManThyroidIIOpTeacherTeacher33
N2745WomanCartilageIIOp、CTeacherTeacher71
N2840ManGulletIOpTeacherTeacher47
N2949WomanRectumIIIOp、CTeacherTeacher123
N3055ManLungIIOp、C、REnterprise leadersEnterprise leaders95

注: Note: Op: operation, C: chemotherapy, R: radiotherapy, T: targeted therapy, E: endocrine therapy

Xu J., Zhou Y., Li J., Tang J., Hu X., Chen Y, & Guo Y. (2023). Cancer patients’ return-to-work adaptation experience and coping resources: a grounded theory study. BMC Nursing, 22, 66.
Publication 2023
Diagnosis Ethics Committees, Research Friend Homo sapiens Malignant Neoplasms Neoplasms Outpatients Patients Pharmacotherapy Physicians Radiotherapy Staging, Cancer System, Endocrine Therapeutics
4
Teleophthalmology Screening for Diabetic Retinopathy
This retrospective medical chart review consisted of collecting data regarding diabetic patients 18 years and older who have participated in the teleophthalmology program offered throughout the state of WV between January 2017 and June 2019. The WVU institutional review board approved the study protocol. The Volk Pictor (Volk Optical, Inc., Mentor, OH, USA) nonmydriatic cameras used by trained nurses and staff acquired 45-degree fundus images from patients at various primary care and endocrinology clinic settings. In these settings, patients waited in rooms with the lights turned off to maximize pupillary dilation sans mydriatic drop administration. Staff would use the handheld fundus cameras to take photographs that were then uploaded and subsequently reviewed by retina specialists. Both eyes were photographed when possible with hopes of acquiring at least one viable image per eye. The number of attempts made was contingent on the judgment of the trained staff acquiring the images and the tolerance demonstrated by the patients being screened for repeated attempts.
Images were graded by a retina specialist at the WVU Eye Institute. These specialists included three WVU board-certified retina faculty and one vitreoretinal fellow—all patients were assigned to have their set of acquired images evaluated by one of these four specialists. Images were noted as gradable or ungradable, and the extent of DR (absent, mild, moderate, severe, or proliferative) and/or DME (absent, mild, moderate, or severe) was described in accordance to the International Classification of DR scale [24 (link)]. Care plan recommendations and suspicion of other pathologies were also noted. The results with their accompanying care plan recommendations were uploaded to the Epic electronic medical record (EMR) for the use of primary care physicians (PCPs) in their advising of diabetic patients in accordance to the American Academy of Ophthalmology’s guidelines for DR follow-up (Fig. 1). Referral recommendations were made in accordance to those proposed by the International Council of Ophthalmology (ICO) and American Diabetes Association (ADA) [25 (link)]—albeit with the decision to recommend referral for suspected DR of any severity. Recommendations could also be made on the basis of other ocular pathologies that were remarked by reviewing ophthalmologists (e.g., age-related macular degeneration, choroidal nevi, colobomas, hypertensive retinopathy, glaucomatous optic nerves). For the purpose of this study, we exclusively followed patients whose screening findings indicated suspicion for diabetic retinopathy of any severity in at least one eye.

Teleophthalmology flow chart

Schofield T., Patel A., Palko J., Ghorayeb G, & Laxson L.C. (2023). Diabetic retinopathy screenings in West Virginia: an assessment of teleophthalmology implementation. BMC Ophthalmology, 23, 93.
Publication 2023
Age-Related Macular Degeneration Choroid Coloboma Diabetes Mellitus Diabetic Retinopathy Ethics Committees, Research Faculty Glaucoma Hypertensive Retinopathy Immune Tolerance Light Mentors Mydriasis Mydriatics Nevus Nurses Ophthalmologists Optic Nerve Patients Pneumocystosis Primary Care Physicians Primary Health Care Retina Specialists System, Endocrine Vision
5
Deconvolution of Pancreatic Cell Types
Deconvolution was performed using the CibersortX algorithm at cibersortx.stanford.edu [74 (link)]. Single-cell transcriptomic profiling dataset of cells in the embryonic pancreas [39 (link)] was used as a reference, including count matrix and metadata labels. Particularly, only cells with pancreatic epithelial or endocrine cell fate were used, corresponding to the annotation of five broader cell types—α cells, β cells, endocrine progenitors, trunk epithelium and tip epithelium [39 (link)]. The reference matrix was built out of the 2589 cells and gene list of 18,565 gene features, as deposited by [39 (link)]. Each cell population counted > 250 cells. The units of the reference matrix were UMI counts. Calculation of the scRNA-seq signature matrix was done in default mode (quantile normalization disabled, minimal expression of 0.75, replicates of 5, sampling of 0.5). Imputation of cell fractions and group-mode expression were used in default settings, with S-mode batch correction enabled, quantile normalization disabled and n = 100 permutations for significance analysis. Sample mixture file was submitted with unfiltered gene list 27,124 features for Isl1CKO and in UMI counts.
Bohuslavova R., Fabriciova V., Lebrón-Mora L., Malfatti J., Smolik O., Valihrach L., Benesova S., Zucha D., Berkova Z., Saudek F., Evans S.M, & Pavlinkova G. (2023). ISL1 controls pancreatic alpha cell fate and beta cell maturation. Cell & Bioscience, 13, 53.
Publication 2023
Cells Embryo Endocrine Cells Epithelial Cells Epithelium Genes Pancreas Single-Cell RNA-Seq System, Endocrine

Top products related to «System, Endocrine»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Immulite 2000 by Siemens
Sourced in Germany, United States, United Kingdom, Italy, Spain, Japan
The Immulite 2000 is an automated immunoassay analyzer designed for in vitro diagnostic testing. It is capable of performing a variety of immunoassay tests, including those for hormones, proteins, and other analytes. The system utilizes chemiluminescent technology for detection and provides automated sample handling, reagent management, and result reporting.
3
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
4
Cobas e411 by Roche
Sourced in Germany, Switzerland, United States, Japan, United Kingdom, Denmark, France, Poland
The Cobas e411 is a compact and fully automated immunoassay analyzer designed for clinical laboratory settings. It is capable of performing a wide range of immunoassay tests, including those for hormones, therapeutic drug monitoring, and infectious disease markers. The Cobas e411 is known for its reliability, ease of use, and efficient throughput.
5
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
6
Vacutainer by BD
Sourced in United States, United Kingdom, Brazil, Germany, Canada, France, Spain, Italy, Switzerland, Australia, Sweden, Belgium, New Zealand, Denmark, Mexico, Jersey, South Sudan, Austria, Japan
The BD Vacutainer is a blood collection system used to collect, process, and preserve blood samples. It consists of a sterile evacuated glass or plastic tube with a closure that maintains the vacuum. The Vacutainer provides a standardized method for drawing blood samples for laboratory analysis.
7
Cobas e411 analyzer by Roche
Sourced in Germany, Switzerland, United States, Japan, France
The Cobas e411 analyzer is a fully automated, random-access immunoassay analyzer designed for clinical diagnostics. It is capable of performing a variety of immunoassay tests to aid in the diagnosis and monitoring of various medical conditions.
8
Cobas e601 by Roche
Sourced in Germany, Switzerland, United States, China, Sweden, United Kingdom, Japan, Canada
The Cobas e601 is an automated immunochemistry analyzer used for in vitro diagnostic testing. It is designed to perform a wide range of immunoassay tests, including those for hormones, tumor markers, and infectious diseases. The Cobas e601 utilizes electrochemiluminescence technology to provide accurate and reliable results.
9
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
10
Mcf 7 by American Type Culture Collection
Sourced in United States, United Kingdom, China, Germany, France, Japan, Italy, Switzerland, Sweden, India, Canada, Egypt, Australia, Holy See (Vatican City State), Brazil
MCF-7 is a cell line derived from human breast adenocarcinoma. It is an adherent epithelial cell line that can be used for in vitro studies.

More about "System, Endocrine"

The Endocrine System is a complex network of glands and hormones that plays a crucial role in regulating numerous physiological processes in the body.
This intricate system includes the pituitary, thyroid, parathyroid, adrenal, and pancreatic glands, as well as other specialized endocrine tissues.
The hormones secreted by these glands travel through the bloodstream to target tissues, where they elicit specific effects, influencing metabolism, reproduction, mood, and more.
Disruptions or imbalances in the Endocrine System can lead to a variety of disorders, such as diabetes, thyroid diseases, and hormonal cancers.
Understanding the Endocrine System is essential for researchers investigating endocrine-related health conditions and developing effective treatments.
Techniques like FBS (Fetal Bovine Serum), Immulite 2000, SAS 9.4, Cobas e411, DMEM (Dulbecco's Modified Eagle Medium), BD Vacutainer, Cobas e601, and SAS version 9.4 are commonly used in endocrine research and analysis.
Researchers can leverage PubCompare.ai's AI-driven platform to enhance reproducibility and accuracy in their Endocrine system studies.
The platform enables users to locate protocols from literature, pre-prints, and patents, and use AI-driven comparisons to identify the best protocols and products for their research, ultimately improving their scientific outcomes.
Whether investigating endocrine disorders, developing new treatments, or exploring the intricate workings of the Endocrine System, researchers can benefit from the wealth of information and tools available, including those from PubCompare.ai.
By staying up-to-date with the latest advancements in this field, researchers can drive progress and make meaningful contributions to the understanding and management of endocrine-related conditions.